Tranylcypromine
Sponsors
National Institute of Mental Health (NIMH), University of Pittsburgh, Vanderbilt University, New York State Psychiatric Institute, Par Pharmaceutical, Inc.
Conditions
AMLAcute Myelogenous LeukemiaAcute Myeloid LeukemiaAnxiety DisordersAutonomic FailureBipolar DisorderBipolar Disorder I or IIDementia
Phase 1
Treatment of Orthostatic Hypotension in Autonomic Failure
CompletedNCT00223691
Start: 2002-03-31End: 2017-01-31Updated: 2017-01-18
Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions
CompletedNCT00653393
Start: 2004-10-31End: 2004-12-31Updated: 2008-04-04
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible
NCT02261779
Start: 2014-09-30End: 2017-09-30Target: 16Updated: 2015-07-07
Study of TCP-ATRA for Adult Patients With AML and MDS
CompletedNCT02273102
Start: 2015-03-02End: 2020-07-01Updated: 2020-07-21
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
NCT02717884
Start: 2015-05-31End: 2021-12-31Target: 60Updated: 2018-10-18
Phase 3
Phase 4
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
CompletedNCT00021528
Start: 2001-07-31End: 2006-09-30Target: 4000Updated: 2009-09-25
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
CompletedNCT00177567
Start: 2001-07-31End: 2004-01-31Target: 60Updated: 2005-09-15
Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression
TerminatedNCT00296686
Start: 2001-09-30End: 2006-08-31Updated: 2012-04-27
PET Biomarkers in Treatment Resistant Depression
TerminatedNCT01031810
Start: 2009-11-30End: 2013-03-31Updated: 2014-09-18
Tranylcypromine Treatment of Bipolar Depression
CompletedNCT01430455
Start: 2011-11-30End: 2014-09-30Updated: 2018-03-15
Unknown Phase
Related Papers
14 more papers not shown